Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology

In this podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER+/HER2- advanced or metastatic breast cancer.

 

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape

The experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions.

 

Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond

A deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

 

Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges

Prof. Dawood and Assoc. Prof. Callahan discuss the next two patient case studies of ER+/HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professionals and patients alike.

 

 

Clinical Takeaways

 

  • Elacestrant was the 1st oral SERD to be FDA approved (January 2023), with optimal efficacy and manageable safety for patients with ESR1 mutated ER+/HER2- advanced or metastatic breast cancer

  • Factors such as disease progression, tumour burden, treatment-related toxicities, patient preferences and quality of life should be considered when deciding whether to adjust current treatment dosage or switch therapies

  • Maximising endocrine therapy options is recommended with and without targeted therapy in ER+/HER2- advanced or metastatic breast cancer

  • ESR1 mutation testing should be done with a liquid biopsy platform at the time of progression on an aromatase inhibitor as well as after subsequent lines of progression

  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Rena D. Callahan, MD, is Associate Clinical Professor of Health Sciences in the Division of Hematology-Oncology in the Department of Medicine at the University of Los Angeles, California (UCLA) David Geffen School of Medicine. She received her undergraduate degree from Yale University, and her medical degree from the University of Pennsylvania in Philadelphia, before completing an internship and residency in Internal Medicine and a fellowship in Hematology-Oncology at UCLA. Dr Callahan is board-certified in Internal Medicine, Medical Oncology, and Hematology. Dr Callahan is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. She has served as principal or sub-investigator for numerous clinical research trials exploring topics related to breast cancer. Dr Callahan is a frequent lecturer on a variety of breast cancer topics and is focused on providing patient centered clinical care in the context of a large clinical practice.

Assoc. Clinical Professor Rena Callahan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Support provided as a speaker from: Gilead, Lilly, Stemline, Seagen

Programme summary
Listen to the podcast now
Other episodes in this series
Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 1: Efficacy, safety and treatment landscape

Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 2: Treatment selection and beyond

Oral SERDS in ER+ breast cancer

Oral SERDS in ER+ breast cancer

Episode 3: Rare cases & treatment challenges

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024

This programme has been sponsored by PMV Pharma.